Sanofi advertising & marketing assignments

Profile subscribers click here for full profile

Selected Sanofi advertising

Sanofi is France's national champion in the healthcare sector and obe of the global top ten. It was formed in 2004 from the hostile takeover of French pharmaceutical giant Aventis by smaller rival Sanofi-Synthelabo. The merged group retained the Sanofi-Aventis name until 2011. A key factor in the takeover was the controversial role played by the French government which successfully steered Aventis away from a combination with Swiss-based Novartis in order to create a local champion that could compete more effectively with American and other European rivals. There have been several other small and medium-sized acquisitions since then. In 2007, the group was reported to have commenced merger talks with US group Bristol-Myers Squibb, which held local rights to Sanofi's Plavix drug, but no deal materialised. In 2009 the group established a presence in the consumer healthcare sector with the purchase of US company Chattem, and made an offer the following year to acquire biotech developer Genzyme. It added to its OTC portfolio in 2017 with a deal swapping its animal health division Merial for the consumer portfolio of German company Boehringer Ingelheim. The following year it agreed to sell its generics division Zentiva. Combined group revenues for 2020 were €36.0bn. Net income soared sixfold to €12.4bn as a result of a one-off gain from the sale of a minority shareholding in US drug developer Regeneron. Prescription pharmaceuticals contributed a total of €25.7bn, with €4.4bn from consumer healthcare and €6.0bn from vaccines division Sanofi Pasteur. Dupixent, a treatment for asthma and other severe allergies produced in partnership with Regeneron, is the group's top-seller, netting Sanofi sales of €3.5bn in 2020. Its lead over the previous best-seller, patent-expired diabetes drug Lantus, widened as the latter slipped to €2.7bn. There are two other blockbusters - Aubagio for MS (sales of €2.0bn) and anticoagulant Lovenox (€1.4bn) and a sizeable collection of other drugs with sales between €500m and €1bn. The closest to breaking €1bn is diabetes medicine Toujeo at €932m. A surprise weakness was Sanofi's failure to deliver a Covid vaccine in 2020. A joint venture with GSK to develop a product got off to a bad start because of a dosing error that meant the final product was too weak to provide a strong enough immune response. A new formula is now in development. In the mean time, Sanofi has donated manufacturing capacity to support the rollout of rival vaccines from Pfizer/BioNtech, Janssen and Moderna. Key OTC brands include Allegra for allergies, painkiller Doliprane and cough/cold remedy Mucosolvan in Europe, laxative Dulcolax and skincare range Gold Bond in the US. In 2019, Sanofi secured US rights for a non-prescription version of Roche's antiviral Tamiflu. Vaccines include Menactra for meningitis and Fluzone. Olivier Brandicourt stepped down in 2019 after four years as CEO, to be replaced by former Novartis manager Paul Hudson.

Capsule checked 7th May 2021

Subscribe to access account assignments

Adbrands Account Assignments tracks account management for the world's leading brands and companies, including details of which advertising agency handles which accounts in which countries for major markets

Subscribers only:
Account assignments & selected contact information

Which agencies handle advertising for Sanofi? Find out more from the Account Assignments database.

Who are the competitors of Sanofi? See Pharmaceutical Sector index for other companies

Historical profile information for Sanofi

Recent stories from Adbrands Update:

Adbrands Daily Update 9th Sep 2021: Sanofi announced the acquisition of US drug developer Kadmon Holdings, just a few weeks after the smaller company's new product Rezurock secured approval from the FDA. The drug is designed to combat chronic graft-versus-host disease (cGVHD) in transplant patients. Analysts estimate Rezurock's sales could reach as much as $1bn annually within the coming years. Kadmon is Sanofi's third acquisition so far this year. It acquired Translate Bio in July and Kiadis in April. Deal price for Kadmon was $1.9bn, almost 80% higher than Kadmon's pre-announcement market valuation.

Adbrands Daily Update 15th Apr 2020: Two of the world's largest vaccine manufacturers - Glaxo SmithKline and Sanofi - announced an unprecedented partnership to develop a product to fight Coronavirus. Sanofi is to revive an antigen that was originally created to battle SARS, while GSK will contribute its "adjuvant" technology which boosts the immune response in recipients. Crucially, their combined manufacturing capacity could allow them to create hundreds of millions of doses by mid-2021. The two companies are respectively the global leader in vaccines and the #4 (after Merck & Pfizer). However, first the companies will have to ensure that any product they develop works. This will require rigorous testing that is unlikely to yield results until the end of this year. "Starting with proven pandemic technologies definitely improves the odds," said Roger Connor, president of GSK's vaccines division. "The world wants to see confirmation that the challenge is being solved, but as with all research there's risk involved with this." At the same time, GSK CEO Emma Walmsley stressed that multiple companies will need to develop different vaccines against the disease. "We're all hoping and we believe the world is going to need more than one vaccine as part of the solution."

Adbrands Daily Update 10th Dec 2019: New Sanofi CEO Paul Hudson has wasted little time since he got his feet under the table in September. He inked his first acquisition this week: US biotech Synthorx, which has a promising cancer immunotherapy drug in trial, for $2.5bn. According to trade sources, he has also been canvassing major shareholders for their views on a potential spin-off of the group's sizeable OTC healthcare division. That could generate as much as $30bn of cash with which to fund further pharmaceutical acquisitions. Hudson also announced he would stop investing in diabetes and cardiovascular research after several years of failure in the search for new blockbuster treatments in those fields. Instead, the company will focus its attention on a smaller spread of more specialised segments, including haemophilia, breast cancer and multiple sclerosis, as well as vaccines. The move away from diabetes is a significant change: blockbuster Lantus was still Sanofi's top-seller in 2018, but sales have been in steady decline, and the company has no new promising diabetes products in its pipeline to replace it.

Adbrands Weekly Update 25th Jan 2018: French dug giant Sanofi inked its biggest deal for years with an agreement to acquire hemophilia specialist Bioverativ for a whopping $11.5bn. It is the group's biggest deal since 2011, when it bought Genzyme for $20bn, but the French group has also been pipped to the post in a number of other recent deals, losing Medivation in 2016 to Pfizer, and Actelion last year to Johnson & Johnson. At the same time, it faces an imminent generic threat to its top-selling product Lantus. Bioverativ's top-selling drugs are Eloctate and Alprolix. However, Sanofi will gain rights to them only in North America and Asia. Rights in the EMEA region are already owned by another company.

Adbrands Weekly Update 24th Aug 2017: There was another blow for Publicis Groupe's media division with the loss of the global account for French healthcare group Sanofi, which had been managed by the old ZenithOptimedia network. WPP's Mindshare becomes the main global agency in all markets except the US and Japan, and WPP will also add selected, as yet undisclosed creative responsibility alongside global incumbents Publicis and Havas. In the US, Havas Media will take over full responsibility for prescription pharmaceuticals, as well as planning for Sanofi's consumer healthcare portfolio, recently boosted by the acquisition of the equivalent division of German company Boehringer Ingelheim. Buying for the OTC business will remain with independent agency KWG, which also hands most creative for that unit. Combined global spend is around €900m.

Subscribe to to access account assignments

All rights reserved © Mind Advertising Ltd 1998-2022